WHAT DOES ABBV-744 IN CLINICAL TRIALS FOR NON-SMALL CELL LUNG CANCER (NSCLC) MEAN?

In Phase A, members will obtain distinctive doses and schedules of oral ABBV-744 tablet to recognize Protected dosing program. Supplemental members is going to be enrolled on the identified monotherapy dosign regimen. In Section B, participants will acquire oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Phase C, parti